Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.
In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...
M&As are stressful for multiple reasons, including role changes and getting laid off when staffs combine. Two talent experts ...
Looking for a biopharma job in New Jersey? Check out the BioSpace list of eight companies hiring life sciences professionals ...
Turn your career aspirations into reality with this step-by-step guide to creating and implementing a strategic professional ...
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...
The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few months later.
The U.S. Court of Federal Claims ruled that Vanda cannot claim a breach of confidentiality for specifications that it did not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback